Resultats de la cerca - Sathej Gopalakrishnan
- Mostrar 1 - 3 resultats de 3
-
1
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy per Deanna J. Brackman, Doerthe Eckert, Rajeev Menon, Ahmed Hamed Salem, Jalaja Potluri, Benjamin D. Smith, Andrew H. Wei, John Hayslip, Dale Miles, Sven Mensing, Sathej Gopalakrishnan, Jiuhong Zha
Publicat 2022Artigo -
2
Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Pha... per Lena Klopp‐Schulze, Sathej Gopalakrishnan, Özkan Yalkinoglu, Yoshihiro Kuroki, Hong Lü, Kosalaram Goteti, Axel Krebs‐Brown, Marco Antonio Ferraz Nogueira Filho, Ulrike Gradhand, Markus Fluck, Jamie Shaw, Jennifer Dong, Karthik Venkatakrishnan
Publicat 2024Artigo -
3
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial per Andrew H. Wei, Pau Montesinos, Vladimir Ivanov, Courtney D. DiNardo, Jan Novák, Kamel Laribi, Inho Kim, Don A. Stevens, Walter Fiedler, Maria Pagoni, Olga Samoilova, Yu Hu, Αchilles Anagnostopoulos, Julie Bergeron, Jing‐Zhou Hou, Vidhya Murthy, Takahiro Yamauchi, Andrew McDonald, Brenda Chyla, Sathej Gopalakrishnan, Qi Jiang, Wellington Mendes, John Hayslip, Panayiotis Panayiotidis
Publicat 2020Artigo
Eines de cerca:
Matèries relacionades
Internal medicine
Medicine
Chemotherapy
Chronic lymphocytic leukemia
Leukemia
Neutropenia
Oncology
Venetoclax
Adverse effect
Alternative medicine
Azacitidine
Biochemistry
Chemistry
Chemotherapy regimen
Clinical trial
Confidence interval
Cytarabine
DNA methylation
Disease
Drug
Drug development
Febrile neutropenia
Gastroenterology
Gene
Gene expression
Hazard ratio
Myeloid leukemia
Pathology
Pharmacodynamics
Pharmacokinetics